Top

Gepubliceerd in:

2019 | OriginalPaper | Hoofdstuk

10. Nucleotidenmetabolisme

Auteur : Prof. dr. F.C. Schuit

Gepubliceerd in: Leerboek metabolisme en voeding

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

In H. 10 bekijken we het metabolisme van purine- en pyrimidinebasen. Deze basen zijn afgeleiden van vier niet-essentiële aminozuren (glycine, serine, glutamine, aspartaat). De de novo synthese van nieuwe basen wordt onderscheiden van de salvageweg, het hergebruik van eerder gemaakte basen. De basen worden geplaatst op een geactiveerde ribosebouwsteen (PRPP) en een netwerk van kinasen zorgt voor een evenwicht tussen alle (desoxy)ribonucleotiden die cellen nodig hebben. De substraatkieskeurigheid van ribonucleotidereductase zorgt voor een evenwicht tussen de vier bouwstenen voor DNA-synthese. Aanmaak van thymine uit uracil vereist thymidylaatsynthase en dihydrofolaatreductase, twee enzymen die vaak doelwit zijn in chemotherapie van kankerpatiënten. De stikstof in overtollige pyrimidinebasen wordt uitgescheiden als ureum; purinebasen worden via het xanthineoxidase omgezet tot urinezuur, dat door de nieren wordt uitgescheiden. Hyperurikemie, een te hoge urinezuurconcentratie in het bloed, kan leiden tot jicht, een chronische metabole ziekte met crisissen die wordt uitgelokt door een combinatie van risicogenen en omgevingsfactoren, zoals voeding.

vorige hoofdstuk Aminozuurmetabolisme

volgende hoofdstuk Voeding

Abbruzzese, J.L. (2002). New applications of gemcitabine & future directions in the management of pancreatic cancer. Cancer. 95, 941–945.

Ajani, J.A. (2008). Optimizing docetaxel chemotherapy in patiënts with cancer of the gastric & gastroesophageal junction: evolution of the docetaxel, cisplatin, & 5-fluorouracil regimen. Cancer. 113, 945–955.

An, S., Kumar, R., Sheets, E.D. & Benkovic, S.J. (2008). Reversible compartmentalization of de novo purine biosynthetic complexes in living cells. Science 320, 103–106.

Avery, O.T., Macleod, C.M. & McCarty, M. (1944). Studies on the chemical nature of the substance inducing transformation of pneumococcal types : induction of transformation by a desoxyribonucleic acid fraction isolated from Pneumococcus type iii. J. Exp. Med. 79, 137–158.

Bailey, C.J. (2009). Orotic aciduria & uridine monophosphate synthase: A reappraisal. J. Inherit. Metab Dis. Jun 27. [Epub ahead of print].

Burra, P. (2009). Hepatitis C. Semin. Liver Dis. 29, 53–65.CrossRef

Cameron, C.E. & Castro, C. (2001). The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr. Opin. Infect. Dis. 14, 757–764.

Cernik, C., Gallina, K. & Brodell, R.T. (2008). The treatment of herpes simplex infections: an evidence-based review. Arch. Intern. Med. 168, 1137–1144.

Chimploy, K., Tassotto, M.L. & Mathews, C.K. (2000). Ribonucleotide reductase, a possible agent in deoxyribonucleotide pool asymmetries induced by hypoxia. J. Biol. Chem. 275, 39267–39271.

Choi, H.K. (2010). A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 22, 165–172.CrossRef

Gaspar, H.B., Aiuti, A., Porta, F., Candotti, F., Hershfield, M.S. & Notarangelo, L.D. (2009). How I treat ADA deficiency. Blood. 114, 3524–3532.

Goker, E., Waltham, M., Kheradpour, A., Trippett, T., Mazumdar, M., Elisseyeff, Y., et al. (1995). Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patiënts with acute lymphoblastic leukemia & is correlated with p53 gene mutations. Blood. 86, 677–684.

Hong, Z. & Cameron, C.E. (2002). Pleiotropic mechanisms of ribavirin antiviral activities. Prog. Drug Res. 59:41-69., 41–69.

Karis, E., Crittenden, D.B., Pillinger, M.H. (2014) Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J. 107, 235–241.CrossRef

Kolz, M., Johnson, T., Sanna, S., Teumer, A., Vitart, V., Perola, M., et al. (2009). Meta-analysis of 28, 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS. Genet. 5, e1000504.

Leoung, G.S., Stanford, J.F., Giordano, M.F., Stein, A., Torres, R.A., Giffen, C.A., et al. (2001). Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patiënts with previous adverse reaction to TMP-SMZ. J. Infect. Dis. 184, 992–997.CrossRef

Li, J., Zheng, L.M., King, I., Doyle, T.W. & Chen, S.H. (2001). Syntheses & antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) & its water-soluble prodrugs. Curr. Med. Chem. 8, 121–133.

Mukherjee, S. & Thrasher, A.J. (2013). Gene therapy for PIDs: progress, pitfalls and prospects. Gene 525, 174–181.

Muul, L.M., Tuschong, L.M., Soenen, S.L., Jagadeesh, G.J., Ramsey, W.J., Long, Z., et al. (2003). Persistence & expression of the adenosine deaminase gene for 12 years & immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 101, 2563–2569.

Nagot, N., Ouedraogo, A., Foulongne, V., Konate, I., Weiss, H.A., Vergne, L., et al. (2007). Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356, 790–799.CrossRef

Nyhan, W.L. (2005). Disorders of purine & pyrimidine metabolism. Mol. Genet. Metab. 86, 25–33.

Oaks, J.L., et al. (2004). Diclofenac residues as the cause of vulture population decline in Pakistan. Nature 427, 630–633.CrossRef

Oettle, H. & Riess, H. (2002). Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 95, 912–922.

Poole, C.L. & James, S.H. (2018) Antiviral therapies for herpesviruses: current agents and new directions. Clin Ther. 40, 1282–1298.

Reginato, A.M., Mount, D.B., Yang, I. & Choi, H.K. (2012). The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 8, 610–621.

Riches, P.L., Wright, A.F. & Ralston, S.H. (2009). Recent insights into the pathogenesis of hyperuricaemia & gout. Hum. Mol. Genet. 18, R177–R184.

Richette, P. & Bardin, T. (2010). Gout. Lancet. 23, 318–328.

Robinson, P.C. (2018) Gout – An update of aetiology, genetics, co-morbidities and management. Maturitas 118, 67–73.CrossRef

Roddy, E. & Doherty, M. (2010). Epidemiology of gout. Arthritis Res. Ther. 12, 223.

Saif, M.W., Choma, A., Salamone, S.J. & Chu, E. (2009). Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J. Natl. Cancer Inst. 101, 1543–1552.

Shao, J., Zhou, B., Chu, B. & Yen, Y. (2006). Ribonucleotide reductase inhibitors & future drug design. Curr. Cancer Drug Targets. 6, 409–431.

Sivera, F., et al. (2014). Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 73, 328–335.CrossRef

Spiegel, E.K., Colman, R.F. & Patterson, D. (2006). Adenylosuccinate lyase deficiency. Mol. Genet. Metab. 89, 19–31.

Stanhope, K.L., et al. (2015) A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 101, 1144–1154.CrossRef

Torres, R.J. & Puig, J.G. (2007). Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet. J. Rare. Dis. 2, 48.

Vaidya, A.B. & Mather, M.W. (2009). Mitochondrial evolution & functions in malaria parasites. Annu. Rev. Microbiol. 63, 249–267.

Vitart, V., Rudan, I., Hayward, C., Gray, N.K., Floyd, J., Palmer, C.N., et al. (2008). SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion & gout. Nat. Genet. 40, 437–442.

Warren, J.W. (2001). Practice guidelines for the treatment of uncomplicated cystitis. Curr. Urol. Rep. 2, 326–329.CrossRef

Wolpin, B.M. & Mayer, R.J. (2008). Systemic treatment of colorectal cancer. Gastroenterology. 134, 1296–1310.

Zhenchuk, A., Lotfi, K., Juliusson, G. & Albertioni, F. (2009). Mechanisms of anti-cancer action & pharmacology of clofarabine. Biochem. Pharmacol. 78, 1351–1359.

Titel: Nucleotidenmetabolisme
Auteur: Prof. dr. F.C. Schuit
Uitgeverij: Bohn Stafleu van Loghum
Boek: Leerboek metabolisme en voeding
Print ISBN: 978-90-368-2357-9

Elektronisch ISBN: 978-90-368-2358-6

Copyright: 2019
DOI: https://doi.org/10.1007/978-90-368-2358-6_10

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen